Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies

Psychiatric Clinics of North America

Volumn 35, Issue 2, 2012, Pages 357-374

  Ross, Stephen ^a  

^a BELLEVUE HOSPITAL CENTER   (United States)

Author keywords

Addiction; Pharmacotherapy; Serotonergic hallucinogens; Treatment

Indexed keywords

18 METHOXYCORONARIDINE; 2,5 DIMETHOXY 4 METHYLAMPHETAMINE; ALIPHATIC AMINE; AMPHETAMINE; AYAHUASCA; BRAIN DERIVED NEUROTROPHIC FACTOR; BUPRENORPHINE; DOPAMINE; ERGOLINE DERIVATIVE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; IBOGAINE; INDOLEALKYLAMINE; KETAMINE; LYSERGIDE; MESCALINE; METHADONE; N,N DIMETHYLTRYPTAMINE; NORIBOGAINE; PHENYLALKYLAMINE; PSILOCIN; PSILOCYBINE; PSYCHEDELIC AGENT; PSYCHOTROPIC AGENT; SEROTONERGIC HALLUCINOGEN; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE;

AFFECT; ALCOHOLISM; BRAIN FUNCTION; COCAINE DEPENDENCE; COGNITION; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DOPAMINERGIC TRANSMISSION; DOWN REGULATION; DRUG ABUSE; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; ELECTROCONVULSIVE THERAPY; GENETIC TRANSDUCTION; HEROIN DEPENDENCE; HUMAN; LIMBIC CORTEX; METHAMPHETAMINE DEPENDENCE; MORPHINE ADDICTION; NERVE CELL PLASTICITY; NEUROBIOLOGY; NEUROIMAGING; NONHUMAN; OPIATE ADDICTION; PHASE 1 CLINICAL TRIAL (TOPIC); PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REINFORCEMENT; RELIGION; REVIEW; SINGLE DRUG DOSE; TOBACCO DEPENDENCE; UPREGULATION; WITHDRAWAL SYNDROME;

ADULT; ANIMALS; BEHAVIOR, ADDICTIVE; CLINICAL TRIALS AS TOPIC; COGNITION; DOPAMINE; DOPAMINE AGONISTS; GLUTAMATES; HALLUCINOGENS; HUMANS; IBOGAINE; LYSERGIC ACID; NEURONAL PLASTICITY; NUCLEUS ACCUMBENS; PHYTOTHERAPY; PREFRONTAL CORTEX; PSILOCYBINE; RELIGION; REWARD; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 84861466898     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2012.04.002     Document Type: Review

References (95)

1. Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, American Psychiatric Association, Arlington (VA). Fourth edition, text revision (DSM-IV-TR).
2. Controlled Substances Act. Pub. L. 91-513, 84 Stat. 1236, enacted October 27, 1970, codified at 21 U.S.C. §801.
3. Leuner H. Hallucinogens as an aid in psychotherapy: basic principles and results. 50 years of LSD: current status and perspectives of hallucinogen research 1994, 175-189. Parthenon, New York. 1st edition. A. Pletscher, D. Ladewig (Eds.).
4. Malleson N. Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry 1971, 118:229-230.
5. Kast E. LSD and the dying patients. Chic Med Sch Q 1966, 26:80-87.
6. Grof S., Goodman L.E., Richards W.A., et al. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 1973, 8(129):129-144.
7. Pahnke W.N. The psychedelic mystical experience in the human encounter with death. Harvard Theol Rev 1969, 62:1-21.
8. Abuzzahab F.S., Anderson J. A review of LSD treatment in alcoholism. Int Pharmacopsychiatry 1971, 6:223-235.
9. Krebs T.S., Johansen P.O. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 2012, [Epub ahead of print].
10. H.R. 4230, 103 D Cong., US Government Printing Office, Washington: 1994 Congressional Record 10 (1994) (enacted).
11. Dobkin de Rios M.D., Grob C.S., Baker J.R. Hallucinogens and redemption. J Psychoactive Drugs 2002, 34(3):239-248.
12. Garrity J.F. Jesus, peyote, and the holy people: alcohol abuse and the ethos of power in Navajo healing. Med Anthropol Q 2000, 14(4):521-542.
13. Fabregas J.M., Gonzalez D., Fondevila S., et al. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend 2010, 111(3):257-261.
14. Halpern J.H., Sherwood A.R., Passie T., et al. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monit 2008, 14(8):SR15-SR22.
15. Doering-Silveira E., Lopez E., Grob C.S., et al. Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J Psychoactive Drugs 2005, 37:141-144.
16. Grob C.S., McKenna D.J., Callaway J.E., et al. Human psychopharmacology of hoasca, a plant hallucinogen use din ritual context in Brazil. J Nerv Ment Dis 1996, 184:86-94.
17. Miranda C.T., Labigalini E., Tacla C. Alternative religion and outcome of alcohol dependence in Brazol. Addiction 1995, 90:847.
18. Menninger K. Navajo peyote use: its apparent safety. Am J Psychiatry 1971, 128:695-699.
19. Halpern J.H., Sherwood A.R., Hudson J.I., et al. Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry 2005, 58:624-631.
20. Glennon R.A. The Pharmacology of Classical Hallucinogens and Related Designer Drugs. Principles of addiction medicine 2009, 215-240. Lippincott Williams & Wilkins, Philadelphia. 4th edition. R.K. Ries, D.A. Fiellin, S.C. Miller (Eds.).
21. Marona-Lewicka D., Thisted R.A., Nichols D.E. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacologia [Berl] 2005, 180:427-435.
22. Alper K.R., Lotsof H.S., Kaplan C.D. The ibogaine medical subculture. J Ethnopharmacol 2008, 115:9-24.
23. Vollenweider F.X., Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 2010, 11(9):642-651.
24. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Bäbler A., et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 1998, 9:3897-3902.
25. Aghajanian G.K., Marek G.J. Serotonin, via 5HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 1999, 825:161-171.
26. Beique J.C., Imad M., Mladenovic L., et al. Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci U S A 2007, 104:9870-9875.
27. Puig M.V., Celada P., az-Mataix L., et al. In vivo modulation of the activity of pyramidal neurons in the rate medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents. Cereb Cortex 2003, 13:870-882.
28. Celada P., Puig M.V., Casanovas J.M., et al. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J Neurosci 2001, 21:9917-9929.
29. Vazquez-Borsetti P., Cortes R., Artigas F. Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors. Cereb Cortex 2009, 19:1678-1686.
30. 11C]raclopride. Neuropsychopharmacology 1999, 20:424-433.
31. Geyer M.A., Vollenweider F.X. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 2008, 29(9):445-453.
32. Nichols D.E. Hallucinogens. Pharmacol Ther 2004, 101:131-181.
33. González-Maeso J., Ang R.L., Yuen T., et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452:93-97.
34. Fribourg M., Moreno J.L., Holloway T., et al. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 2011, 147(5):1011-1023.
35. Baler R.D., Volkow N.D. Drug addiction: the neurobiology of disrupted self-control. Trends Mol Med 2006, 12(12):559-566.
36. O'Brien C.P. Drug addiction and drug abuse. Goodman and Gilman's the pharmacological basis of therapeutics 2001, 574-639. McGraw-Hill, New York. J.G. Hardman, L.E. Limbird, P.B. Molinoff (Eds.).
37. 1 dopamine receptors. Psychopharmacology [Berl] 1995, 118:401-409.
38. 2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro. Life Sci 1998, 63:215-222.
39. Maisonneuve I.M., Keller R.W., Glick S.D. Interactions of ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study. Eur J Pharmacol 1991, 199(1):35-42.
40. Glick S.D., Kuehne M.E., Raucci J., et al. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res 1994, 657(1-2):14-22.
41. Glick S.D., Maisonneuve I.M., Dickinson H.A. 18-MC reduced methamphetamine and nicotine self-administration in rats. NeuroReport 2000, 11(9):2013-2015.
42. Taraschenko O.D., Shulan J.M., Maisonneuve I.M., et al. 18-MC acts in the medial habenula and interpeduncular nucleus to attenuate dopamine sensitization to morphine in the nucleus accumbens. Synapse 2007, 61(7):547-560.
43. Benwell M.E., Holtom P.E., Moran R.J., et al. Neurochemical and behavioural interactions between ibogaine and nicotine in the rat. Br J Pharmacol 1996, 117(4):743-749.
44. Maisonneuve I.M., Mann G.L., Deibel C.R., et al. Ibogaine and the dopaminergic response to nicotine. Psychopharmacology [Berl] 1997, 129(3):249-256.
45. Glick S.D., Maisonneuve I.M., Visker K.E., et al. 18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats. Psychopharmacology [Berl] 1998, 139(3):274-280.
46. 2 receptors in rat brain. Neuropsychopharmacology 1990, 3:137-148.
47. Hallucinogens and dissociative drugs. National Institute on Drug Abuse research report series, vol. 01-4209 2001, NIDA, National Institute on Drug Abuse, Rockville (MD).
48. LSD NIDA info facts 2005, NIDA, National Institute on Drug Abuse, Rockville (MD).
49. Dobkin de Rios M. Hallucinogens: cross-cultural perspective 1984, Waveland Press, Prospect Heights (IL).
50. Fernandez J.W. Bwiti: an ethnography of religious imagination in Africa 1982, Princeton University Press, Princeton (NJ).
51. Lotsof H.S., Alexander N.E. Case studies of ibogaine treatment: implications for patients' management strategies. Alkaloids Chem Biol 2001, 56:293-313.
52. Mash D.C., Kovera C.A., Buck B.E., et al. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann NY Acad Sci 1998, 844:274-292.
53. Schechter M.D., Gordon T.L. Comparison of the behavioral effects of ibogaine from three sources: mediation of discriminative activity. Eur J Pharmacol 1993, 249:79-84.
54. Alper K.R., Lotsof H.S., Frenken G.M., et al. Treatment of acute opioid withdrawal with ibogaine. Am J Addict 1999, 8:234-242.
55. Alper K.R., Beal D., Kaplan C.D. A contemporary history of ibogaine in the United States and Europe. Alkaloids Chem Biol 2001, 56:249-281.
56. Sheppard S.G. A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat 1994, 11:379-385.
57. Cappendijk S.L., Dzoljic M.R. Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur J Pharmacol 1993, 241:261-265.
58. He D.Y., McGough N.N., Ravindranathan A., et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci 2005, 25:619-628.
59. Aceto M.D., Bowman E.R., Harris L.S., et al. Dependence studies of new compounds in the rhesus monkey and mouse. NIDA Res Monogr 1991, 119:513-558.
60. Molinari H.H., Maisonneuve I.M., Glick S.D. Ibogaine neurotoxicity: a re-evaluation. Brain Res 1996, 737(1-2):255-262.
61. Maas U., Strubelt S. Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction. Med Hypotheses 2006, 67(4):960-964.
62. Alper K., Lotsof H.S. The use of ibogaine in the treatment of addictions. Hallucinogens and healing 2007, Praeger, Greenwood Publishing Group, Westport (CT). M. Winkelman, T. Roberts (Eds.).
63. Maciulaitis R., Kontrimaviciute V., Bressolle F.M.M., et al. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Hum Exp Toxicol 2008, 27:181-194.
64. Mash D.C., Kovera C.A., Pablo J., et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci 2000, 914:394-401.
65. Pearl S.M., Maisonneuve I.M., Glick S.D. Prior morphine exposure enhances ibogaine antagonism of morphine-induced dopamine release in rats. Neuropharmacology 1996, 35:1779-1784.
66. Sunder Sharma S., Bhargava H.N. Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice. Pharmacology 1998, 57(5):229-232.
67. Kalivas P.W. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009, 10:561-572.
68. Blum K., Chen A.L., Chen T.J.H., et al. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor Biol Med Model 2008, 5:24-39.
69. Swendsen J., Le Moal M. Individual vulnerability to addiction. Ann N Y Acad Sci 2011, 1216:73-85.
70. Kalivas P.W., Volkow N.D. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005, 162:1403-1413.
71. Volkow N.D., Fowler J.S., Wang G.J., et al. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004, 9:557-569.
72. Boundy V.A., Pacheco M.A., Guan W., et al. Agonists and antagonists differentially regulate the high affinity state of the D2L receptor in human embryonic kidney 293 cells. Mol Pharmacol 1995, 48:956-964.
73. Boundy V.A., Lu L., Molinoff P.B. Differential coupling of rat D2 dopamine receptor isoforms expressed in Spodoptera frugiperda insect cells. J Pharmacol Exp Ther 1996, 276:784-794.
74. Noble E.P., Noble R.E., Ritchie T., et al. D2 dopamine receptor gene and obesity. Int J Eat Disord 1994, 15:205-217.
75. Pohjalainen T., Rinne J.O., Nagren K., et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998, 3:256-260.
76. Noble E.P., Blum K., Ritchie T., et al. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 1991, 48:648-654.
77. Ross S., Peselow E. Pharmacotherapies for addictive disorders. Clin Neuropharmacol 2009, 32(5):277-289.
78. 2 receptor binding in rat brain. Eur J Pharmacool 1985, 109:421-425.
79. 2 receptors. Life Sci 1988, 42:2439-2445.
80. 2 receptors by DOM treatment. Eur J Pharmacol 1989, 163:145-149.
81. Frokjaer V.G., Mortensen E.L., Nielsen F.A., et al. Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry 2008, 63(6):569-576.
82. Sinha R., Li C.S. Imaging stress- and cue-induced drug and alcohol craving: association with relapse and clinical implications. Drug Alcohol Rev 2007, 26(1):25-31.
83. Vaidya V.A., Marek G.J., Aghajanian G.K., et al. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 1997, 17:2785-2795.
84. Cavus I., Duman R.S. Influence of estradiol, stress, and 5-HT2A agonist treatment on brain-derived neurotrophic factor expression in female rats. Biol Psychiatry 2003, 54:59-69.
85. Ghitza U.E., Zhai H., Wu P., et al. Role of BDNF and GDNF in drug reward and relapse: a review. Neurosci Biobehav Rev 2010, 35:157-171.
86. Ron D., Janak P.H. GDNF and addiction. Rev Neurosci 2005, 16:277-285.
87. He D.Y., Ron D. Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addictive drug, Ibogaine. Faseb J 2006, 20:E1-E8.
88. Maissoneuve I.M., Glick S.D. Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment. Pharmacol Biochem Behav 2003, 75(3):607-618.
89. Kalivas P.W. Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity. Dialogues Clin Neurosci 2007, 9:389-397.
90. Kalivas P.W. The glutamate homeostasis hypothesis of addiction. Nature Rev Neurosci 2009, 10:561-572.
91. Javitt D.C., Schoepp D., Kalivas P.W., et al. Translating glutamate: from pathophysiology to treatment. Neuroscience 2011, 102(3):1-13.
92. O'Brien C.P., Jones R.T. Methodological issues in the evaluation of a medication for its potential benefits in enhancing psychotherapy. 50 years of LSD: current status and perspectives of hallucinogens 1994, 213-222. Parthenon, New York. 1st edition.
93. Brewer J.A., Bowen S., Smith J.T., et al. Mindfulness-based treatments for co-occurring depression and substance use disorders: what can we learn from the brain?. Addiction 2010, 105(10):1698-1706.
94. Relapse prevention: Maintenance strategies in the treatment of addictive behaviors 1985, Guilford Press, New York. G.A. Marlatt, J.R. Gordon (Eds.).
95. Bowen W.T., Soskin R.A., Chotlos J.W. Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism. J Nerv Ment Dis 1970, 150(2):111-118.